
Although potentially helpful, the changes in the law may have limited effect on the FDA approval process. Currently, drugs that come before the FDA's Division of Neurological Products (DNP) have a more difficult path to approval than drugs that come under the FDA's Division of Psychiatry Products (DPP).
https://www.cbsnews.com/news/working-president-obama-signs-the-21st-century-cures-act/